바이오의약품 안전성 시험 시장 : 제공 제품별, 시험 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2031년)

The global biologics safety testing market is estimated to reach USD 9.66 billion by 2031 from USD 5.57 billion in 2026, at a CAGR of 11.6% during the forecast period of 2026 to 2031. The global biologics safety testing market is projected to witness strong growth over the forecast period, supported by the rising biologics and biosimilars pipeline and the growth of advanced modalities such as cell & gene therapies and mRNA products.

Market estimates from published industry sources indicate robust growth through 2031, driven by strong expansion in biologics development and manufacturing, as well as rising demand for stringent safety testing to ensure product quality. However, the high cost of advanced testing equipment, limited specialized expertise, and regulatory divergence across regions are expected to remain key factors restraining broader market expansion.

"The assays, kits, and reagents segment accounted for the largest share by product in the biologics safety testing market in 2025."

Based on product, the biologics safety testing market is broadly segmented into assays, kits & reagents, and instruments. In 2025, assays, kits, and reagents accounted for the largest share of the biologics safety testing market, driven by their widespread use in routine applications such as endotoxin, mycoplasma, sterility, and viral detection testing. Their ease of use, reliability, and compatibility with automated and high-throughput systems make them essential across laboratories. Additionally, their cost-effectiveness and ability to deliver rapid, reproducible results support consistent demand from biopharmaceutical companies, CROs, and research institutions globally.

"The monoclonal antibodies and therapeutic proteins segment accounted for the largest share of the biologics safety testing product applications market in 2025."

Based on application, the global biologics safety testing product market is segmented into vaccines, monoclonal antibodies & therapeutic proteins, cellular & gene therapy products, blood & blood products, and other applications. The monoclonal antibodies & therapeutic proteins segment accounted for the largest share of the biologics safety testing product market in 2025, driven by their extensive use in treating chronic and complex diseases. The growing pipeline, increasing approvals, and large-scale commercial production of these biologics require rigorous safety testing. Additionally, stringent regulatory requirements and the need to ensure product purity, potency, and consistency further contribute to the segment's market position globally.

"The Asia Pacific is growing at the highest CAGR in the biologics safety testing market from 2026 to 2031."

The biologics safety testing market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, supported by expanding biopharmaceutical manufacturing, increasing adoption of biologics and biosimilars, and rising clinical trial activity. Growth is further driven by improving regulatory frameworks, and the presence of key regional and global players such as Samsung Biologics and WuXi AppTec is actively strengthening biologics development and safety testing capabilities.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side - 30%
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Lonza
• FUJIFILM Corporation
• Sartorius AG
• F. Hoffmann- La Roche Ltd.
• Charles River Laboratories
• bioMerieux
• WuXi AppTec
• SGS Societe Generale de Surveillance SA
• Sotera Health
• Samsung Biologics
• GenScript
• Agilent Technologies, Inc.
• Syngene International Limited
• Eurofins Scientific
• Laboratory Corporation of America Holdings
• Bio-Rad Laboratories, Inc.
• QIAGEN

Research Coverage

This research report categorizes the biologics safety testing market by offering, by test type, by application (product & service applications), by end user (product & service end users), and by region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the biologics safety testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the biologics safety testing market. This report covers competitive analysis of top players and upcoming startups in the biologics safety testing market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising biologics and biosimilars pipeline, stringent and evolving regulatory requirements, growth of advanced modalities like cell & gene therapies and mRNA products, expansion of CDMOs and the structural shift toward outsourced testing), restraints (high cost of advanced testing equipment and limited specialized expertise, regulatory divergence across regions), opportunities (growing focus on next-generation therapeutics, the shift toward animal-free testing approaches) and challenges (assay standardization gap) influencing the growth of biologics safety testing market
• Product Development/Innovation: Detailed insights on newly launched products of the biologics safety testing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the biologics safety testing market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biologics safety testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Charles River Laboratories (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
• 3.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY OFFERING & REGION
• 3.3 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising biologics and biosimilars pipeline
    • 4.2.1.2 Stringent and evolving regulatory requirements
    • 4.2.1.3 Growth of advanced modalities like cell & gene therapies and mRNA products
    • 4.2.1.4 Rising demand for outsourced development/manufacturing and testing
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of advanced testing equipment and limited specialized expertise
    • 4.2.2.2 Regulatory divergence across regions
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing focus on next-generation therapeutics
    • 4.2.3.2 Shift toward animal-free testing approaches
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Assay standardization gap
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL BIOLOGICS SAFETY TESTING MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025
  • 5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025
• 5.6 KEY CONFERENCES & EVENTS
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 IMPACT OF US TARIFFS-BIOLOGICS SAFETY TESTING MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 KEY TARIFF RATES
  • 5.9.3 PRICE IMPACT ANALYSIS
  • 5.9.4 IMPACT ON COUNTRIES/REGIONS
    • 5.9.4.1 North America
    • 5.9.4.2 Europe
    • 5.9.4.3 Asia Pacific
  • 5.9.5 IMPACT ON END-USE INDUSTRIES
    • 5.9.5.1 Pharmaceutical and biotechnology companies
    • 5.9.5.2 CROs & CDMOs
    • 5.9.5.3 Academic & Research Institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 POLYMERASE CHAIN REACTION (PCR)
  • 6.1.2 NEXT-GENERATION SEQUENCING (NGS)
• 6.2 ADJACENT TECHNOLOGIES
  • 6.2.1 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
• 6.3 COMPLEMENTARY TECHNOLOGIES
  • 6.3.1 LAB-ON-A-CHIP (LOC) SYSTEMS
  • 6.3.2 HIGH-CONTENT SCREENING (HCS)
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOLOGICS SAFETY TESTING PATENTS, 2015-2025
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON BIOLOGICS SAFETY TESTING MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOLOGICS SAFETY TESTING MARKET
  • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN BIOLOGICS SAFETY TESTING MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 BIOLOGICS SAFETY TESTING MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 SERVICES
  • 9.2.1 VIRUS SAFETY TESTING SERVICES
    • 9.2.1.1 Rising focus on development of advanced therapies to drive growth
  • 9.2.2 STERILITY TESTING SERVICES
    • 9.2.2.1 Need for sterility testing at each stage of drug development to propel growth
  • 9.2.3 MYCOPLASMA TESTING SERVICES
    • 9.2.3.1 Increasing focus on development of biologics and biosimilars to promote growth
  • 9.2.4 ENDOTOXIN TESTING SERVICES
    • 9.2.4.1 Stringent regulatory requirements to drive market
  • 9.2.5 BIOBURDEN TESTING SERVICES
    • 9.2.5.1 Rising adoption of advanced testing solutions for contamination risk mitigation to propel the growth
  • 9.2.6 OTHER BST SERVICES
• 9.3 PRODUCTS
  • 9.3.1 ASSAYS, KITS, AND REAGENTS
    • 9.3.1.1 Detection kits
      • 9.3.1.1.1 Expanding advanced biologics pipelines and faster QC workflows are lifting demand for high-sensitivity detection kits
    • 9.3.1.2 Endotoxin testing reagents
      • 9.3.1.2.1 Regulatory acceptance of recombinant methods and shift to simpler, animal-free QC workflows are accelerating demand for endotoxin testing reagents
    • 9.3.1.3 Sterility testing media & kits
      • 9.3.1.3.1 Rapid release needs and shift toward standardized aseptic QC strengthen demand for sterility testing media and kits
    • 9.3.1.4 Bioburden enumeration
      • 9.3.1.4.1 Stricter contamination control expectations and faster microbiology workflows drive demand for bioburden enumeration solutions
    • 9.3.1.5 Other BST assays, kits, and reagents
  • 9.3.2 INSTRUMENTS
    • 9.3.2.1 Detection & imaging systems
      • 9.3.2.1.1 Rapid molecular testing, automated microbiology, and standardized QC workflows are increasing the demand
    • 9.3.2.2 Sequencing instruments
      • 9.3.2.2.1 Wider adoption of NGS-based viral safety workflows and smaller, more accessible platforms support demand
    • 9.3.2.3 Automated sterility testing systems
      • 9.3.2.3.1 Shorter release timelines and wider adoption of rapid microbiology to drive growth
    • 9.3.2.4 Other BST instruments

10 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE

• 10.1 INTRODUCTION
• 10.2 VIRUS SAFETY TESTS
  • 10.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
• 10.3 STERILITY TESTS
  • 10.3.1 MANDATORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO PROMOTE SEGMENT GROWTH
• 10.4 ENDOTOXIN TESTS
  • 10.4.1 GROWING R&D ACTIVITIES FOR DEVELOPMENT OF BIOLOGICS TO PROMOTE THE GROWTH OF THE SEGMENT
• 10.5 MYCOPLASMA TESTS
  • 10.5.1 RISING CONCERN FOR CELL CULTURE CONTAMINATION TO DRIVE THE SEGMENT GROWTH
• 10.6 BIOBURDEN TESTS
  • 10.6.1 GROWING CONCERNS FOR DRUG SAFETY STANDARDS HAVE INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY
• 10.7 RESIDUAL HCP & DNA DETECTION TESTS
  • 10.7.1 STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO CONTRIBUTE TO THE SEGMENT GROWTH
• 10.8 OTHER TESTS

11 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 MONOCLONAL ANTIBODIES & THERAPEUTIC PROTEINS
  • 11.2.1 GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO CONTRIBUTE TO THE MARKET SHARE
• 11.3 VACCINES
  • 11.3.1 EXPANDING VACCINE PLATFORM COMPLEXITY AND STRICTER GLOBAL QUALITY EXPECTATIONS TO DRIVE MARKET GROWTH
• 11.4 CELLULAR & GENE THERAPY PRODUCTS
  • 11.4.1 GROWING PRODUCT MANUFACTURING COMPLEXITY IS ACCELERATING DEMAND
• 11.5 BLOOD & BLOOD PRODUCTS
  • 11.5.1 GROWING DEMAND FOR BLOOD PRODUCTS TO PROMOTE MARKET GROWTH
• 11.6 OTHER APPLICATIONS

12 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 MONOCLONAL ANTIBODY & THERAPEUTIC PROTEIN SAFETY TESTING
  • 12.2.1 EXPANDING ANTIBODY PIPELINES AND RISING BIOSIMILAR MANUFACTURING ARE DRIVING GROWTH
• 12.3 VACCINE SAFETY TESTING
  • 12.3.1 EXPANSION OF VACCINE SAFETY TESTING DRIVEN BY ADVANCED PLATFORMS AND REGULATORY STRINGENCY
• 12.4 CELLULAR & GENE THERAPY SAFETY TESTING
  • 12.4.1 EXPANDING ADVANCED THERAPY MANUFACTURING AND TIGHTER STERILITY REQUIREMENTS TO ACCELERATE DEMAND
• 12.5 BLOOD & BLOOD PRODUCT SAFETY TESTING
  • 12.5.1 PLASMA PRODUCT SAFETY REQUIREMENTS AND NEW ASSAY APPROVALS TO DRIVE MARKET GROWTH
• 12.6 OTHER APPLICATIONS

13 BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 RISING ADOPTION OF SAFETY TESTING PRODUCTS BY BIOPHARMA MANUFACTURERS
• 13.3 CROS & CDMOS
  • 13.3.1 RISING OUTSOURCING OF BIOLOGICS DEVELOPMENT AND MANUFACTURING ACCELERATES MARKET GROWTH
• 13.4 ACADEMIC & RESEARCH INSTITUTES
  • 13.4.1 EXPANDING TRANSLATIONAL BIOLOGICS RESEARCH AND EARLY-STAGE PLATFORM DEVELOPMENT DRIVES MARKET GROWTH
• 13.5 OTHER END USERS

14 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 14.2.1 GROWING OUTSOURCING OF SAFETY TESTING SERVICES BY BIOPHARMA COMPANIES TO AID GROWTH
• 14.3 ACADEMIC & RESEARCH INSTITUTES
  • 14.3.1 RISING TRANSLATIONAL RESEARCH IS DRIVING ADOPTION OF BIOLOGICS SAFETY TESTING SERVICES IN ACADEMIC INSTITUTES
• 14.4 OTHER END USERS

15 BIOLOGICS SAFETY TESTING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 US
    • 15.2.1.1 Leading biopharma industry, federal funding, mature ecosystem, and biologics development activity to propel market growth
  • 15.2.2 CANADA
    • 15.2.2.1 Investments for expanding biomanufacturing capacity to propel market growth
• 15.3 EUROPE
  • 15.3.1 GERMANY
    • 15.3.1.1 Expansion initiatives by key market players to support market growth
  • 15.3.2 UK
    • 15.3.2.1 Emphasis on vaccine manufacturing and biotech R&D to drive market
  • 15.3.3 FRANCE
    • 15.3.3.1 Strong government funding driving biologics innovation and testing demand
  • 15.3.4 ITALY
    • 15.3.4.1 Manufacturing investment and strong R&D intensity support market growth
  • 15.3.5 SPAIN
    • 15.3.5.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market
  • 15.3.6 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 CHINA
    • 15.4.1.1 Rising biologics development driving market growth
  • 15.4.2 JAPAN
    • 15.4.2.1 Government initiatives and expansion of biopharma companies to boost market
  • 15.4.3 INDIA
    • 15.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies drive market growth
  • 15.4.4 SOUTH KOREA
    • 15.4.4.1 Growing focus on advancing bioprocessing sector to drive market
  • 15.4.5 AUSTRALIA
    • 15.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
  • 15.4.6 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 BRAZIL
    • 15.5.1.1 Expanding biologics manufacturing investment and rising clinical development activity are driving market growth
  • 15.5.2 MEXICO
    • 15.5.2.1 Increasing government support for biopharmaceutical production to drive market
  • 15.5.3 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 GCC COUNTRIES
    • 15.6.1.1 Saudi Arabia
      • 15.6.1.1.1 Increasing healthcare expenditure and rising focus of key players on expansion to support growth
    • 15.6.1.2 United Arab Emirates
      • 15.6.1.2.1 Developing biopharma sector to drive market
    • 15.6.1.3 Rest of GCC countries
  • 15.6.2 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 RISING AWARENESS AND COLLABORATIVE INITIATIVES TO DRIVE ADOPTION

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 16.3 REVENUE ANALYSIS
• 16.4 MARKET SHARE ANALYSIS
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Offering footprint
    • 16.5.5.4 Test type footprint
    • 16.5.5.5 Application footprint of companies
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of key startups/SMEs
• 16.7 COMPANY VALUATION & FINANCIAL METRICS
• 16.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES
  • 16.9.2 DEALS
  • 16.9.3 EXPANSIONS

17 COMPANY PROFILES

• 17.1 MAJOR PALYER
  • 17.1.1 THERMO FISHER SCIENTIFIC INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products/Services/Solutions offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Service launches
      • 17.1.1.3.2 Deals
      • 17.1.1.3.3 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses and competitive threats
  • 17.1.2 CHARLES RIVER LABORATORIES
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products/Services/Solutions offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product and service launches
      • 17.1.2.3.2 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses and competitive threats
  • 17.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products/Services/Solutions offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Deals
      • 17.1.3.3.2 Expansions
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses and competitive threats
  • 17.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products/Services/Solutions offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product launches
      • 17.1.4.3.2 Expansions
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Key strengths
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses and competitive threats
  • 17.1.5 MERCK KGAA
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products/Services/Solutions offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Expansions
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Key strengths
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses and competitive threats
  • 17.1.6 SARTORIUS AG
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products/Services/Solutions offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product launches
  • 17.1.7 LONZA
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products/Services/Solutions offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
      • 17.1.7.3.2 Deals
  • 17.1.8 FUJIFILM CORPORATION
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products/Services/Solutions offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Expansions
  • 17.1.9 BIOMERIEUX
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products/Services/Solutions offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches
      • 17.1.9.3.2 Deals
  • 17.1.10 MARAVAI LIFESCIENCES
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products/Services/Solutions offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Deals
  • 17.1.11 WUXI APPTEC
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products/Services/Solutions offered
  • 17.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products/Services/Solutions offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Service launches
      • 17.1.12.3.2 Expansions
  • 17.1.13 SOTERA HEALTH
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products/Services/Solutions offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Service launches
      • 17.1.13.3.2 Expansions
  • 17.1.14 SAMSUNG BIOLOGICS
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products/Services/Solutions offered
    • 17.1.14.3 Recent developments
      • 17.1.14.3.1 Deals
      • 17.1.14.3.2 Expansions
  • 17.1.15 GENSCRIPT
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products/Services/Solutions offered
  • 17.1.16 AGILENT TECHNOLOGIES, INC.
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products/Services/Solutions offered
  • 17.1.17 SYNGENE INTERNATIONAL LIMITED
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products/Services/Solutions offered
  • 17.1.18 EUROFINS SCIENTIFIC
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products/Services/Solutions offered
    • 17.1.18.3 Recent developments
      • 17.1.18.3.1 Service launches
      • 17.1.18.3.2 Expansions
  • 17.1.19 BIO-RAD LABORATORIES, INC.
    • 17.1.19.1 Business overview
    • 17.1.19.2 Products/Services/Solutions offered
    • 17.1.19.3 Recent developments
      • 17.1.19.3.1 Product launches
      • 17.1.19.3.2 Deals
  • 17.1.20 QIAGEN
    • 17.1.20.1 Business overview
    • 17.1.20.2 Products/Services/Solutions offered
    • 17.1.20.3 Recent developments
      • 17.1.20.3.1 Product launches
• 17.2 OTHER PLAYERS
  • 17.2.1 PROMEGA CORPORATION
  • 17.2.2 CATALENT, INC.
  • 17.2.3 ASSOCIATES OF CAPE COD, INC.
  • 17.2.4 CLEAN BIOLOGICS
  • 17.2.5 PATHOQUEST
  • 17.2.6 PACIFIC BIOLABS
  • 17.2.7 ARL BIO PHARMA, INC.
  • 17.2.8 FRONTAGE LABS
  • 17.2.9 CREATIVE BIOGENE
  • 17.2.10 ADVAXIA BIOLOGICS

18 RESEARCH METHODOLOGY

• 18.1 RESEARCH DATA
  • 18.1.1 SECONDARY DATA
  • 18.1.2 PRIMARY DATA
• 18.2 MARKET ESTIMATION METHODOLOGY
  • 18.2.1 MARKET SIZE ESTIMATION
  • 18.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 18.2.3 TOP-DOWN APPROACH
• 18.3 MARKET GROWTH RATE PROJECTIONS
• 18.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 18.5 RESEARCH ASSUMPTIONS
• 18.6 RESEARCH LIMITATIONS
• 18.7 RISK ANALYSIS

19 APPENDIX

• 19.1 DISCUSSION GUIDE
• 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 19.3 CUSTOMIZATION OPTIONS
• 19.4 RELATED REPORTS
• 19.5 AUTHOR DETAILS